GYR-767 series (Aviragen Therapeutics)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameGYR-767 series (Aviragen Therapeutics)
Drug Alias NameDNA gyrase inhibitor (Prolysis)DNA topoisomerase IV inhibitors (Biota)anti-bacterial DNA supercoilinginhibitor (Prolysis)DNA gyrase inhibitors (Biota)GYR-767 series (Biota) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATPase inhibitorsTopoisomerase IV inhibitorsBacterial DNA gyrase degraders
TargetsTopoisomerase IVBacterial DNA gyraseATPase
Therapy Area/IndicationsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProlysis Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiota Holdings LtdProlysis LtdVaxart Inc
Active IndicationsN/A
Inactive IndicationsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A